|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Cytomx Therapeutics, Inc. (CTMX) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
65,160,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile CytomX Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company. Co. is developing an antibody-based therapeutics created using its Probody® therapeutic technology platform. Co.'s products include: Praluzatamab ravtansine, which is an activated antibody-drug conjugates directed against CD166, a tumor target previously considered undruggable due to its high expression on normal tissues; CX-2029, which opens a therapeutic window for targeting CD71; Pacmilimab, which is a Probody therapeutic against PD-L1, a clinically and commercially validated cancer target; and BMS-986249 and BMS-986288, which is the Probody versions of ipilimumab.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
47,819 |
75,591 |
103,916 |
162,805 |
| Total Sell Value |
$99,726 |
$138,068 |
$174,902 |
$267,502 |
| Total People Sold |
5 |
5 |
5 |
8 |
| Total Sell Transactions |
5 |
10 |
14 |
26 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Mccarthy Sean A. |
President and CEO |
• • – |
2020-05-29 |
4 |
A |
$5.11 |
$5,916 |
D/D |
1,158 |
85,464 |
|
- |
|
| Mccarthy Sean A. |
President and CEO |
• • – |
2020-05-12 |
4 |
AS |
$15.00 |
$540,000 |
D/D |
(36,000) |
84,306 |
|
- |
|
| Mccarthy Sean A. |
President and CEO |
• • – |
2020-05-12 |
4 |
OE |
$1.13 |
$40,820 |
D/D |
36,000 |
120,306 |
|
- |
|
| Mccarthy Sean A. |
President and CEO |
• • – |
2019-11-30 |
4 |
A |
$5.32 |
$5,747 |
D/D |
1,080 |
84,306 |
|
- |
|
| Mccarthy Sean A. |
President and CEO |
• • – |
2019-09-30 |
4 |
GD |
$0.00 |
$0 |
D/D |
4,500 |
7,809 |
|
- |
|
| Knifsend Robin |
Principal Accounting Officer |
• – – |
2019-05-31 |
4 |
A |
$8.21 |
$14,878 |
D/D |
1,812 |
2,791 |
|
- |
|
| Rowland Lloyd A |
General Counsel |
• – – |
2019-05-31 |
4 |
A |
$8.21 |
$14,878 |
D/D |
1,812 |
11,791 |
|
- |
|
| Mccarthy Sean A. |
President and CEO |
• • – |
2019-05-31 |
4 |
A |
$8.21 |
$5,707 |
D/D |
695 |
83,226 |
|
- |
|
| Knifsend Robin |
Principal Accounting OfficerOf |
• – – |
2019-05-22 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
979 |
|
- |
|
| Jones Elaine V |
Director |
– • – |
2019-05-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
142 |
|
- |
|
| Gluck Frederick W |
Director |
– • – |
2019-04-08 |
4/A |
GD |
$0.00 |
$0 |
D/D |
3,900 |
237,015 |
|
- |
|
| Gluck Frederick W |
Director |
– • – |
2019-04-08 |
4 |
GD |
$0.00 |
$0 |
I/I |
7,800 |
18,211 |
|
- |
|
| Rowland Lloyd A |
General Counsel |
• – – |
2019-03-04 |
4 |
B |
$10.33 |
$92,970 |
D/D |
9,000 |
9,979 |
2.74 |
- |
|
| Ray Debanjan |
Chief Financial Officer |
• – – |
2018-12-12 |
4 |
AS |
$15.00 |
$45,000 |
D/D |
(3,000) |
5,928 |
|
- |
|
| Ray Debanjan |
Chief Financial Officer |
• – – |
2018-12-12 |
4 |
OE |
$1.45 |
$4,347 |
D/D |
3,000 |
8,928 |
|
- |
|
| Rowland Lloyd A |
General Counsel |
• – – |
2018-11-30 |
4 |
A |
$11.73 |
$11,484 |
D/D |
979 |
979 |
|
- |
|
| Mccarthy Sean A. |
President and CEO |
• • – |
2018-11-30 |
4 |
A |
$11.73 |
$5,490 |
D/D |
468 |
82,531 |
|
- |
|
| Ray Debanjan |
Chief Financial Officer |
• – – |
2018-10-01 |
4 |
AS |
$18.46 |
$55,380 |
D/D |
(3,000) |
5,928 |
|
- |
|
| Ray Debanjan |
Chief Financial Officer |
• – – |
2018-10-01 |
4 |
OE |
$1.45 |
$4,347 |
D/D |
3,000 |
8,928 |
|
- |
|
| Ray Debanjan |
Chief Financial Officer |
• – – |
2018-09-04 |
4 |
AS |
$22.39 |
$67,170 |
D/D |
(3,000) |
5,928 |
|
- |
|
| Ray Debanjan |
Chief Financial Officer |
• – – |
2018-09-04 |
4 |
OE |
$1.45 |
$4,347 |
D/D |
3,000 |
8,928 |
|
- |
|
| Mccarthy Sean A. |
President and CEO |
• • – |
2018-09-04 |
4 |
AS |
$21.86 |
$285,343 |
D/D |
(13,052) |
82,063 |
|
- |
|
| Mccarthy Sean A. |
President and CEO |
• • – |
2018-09-04 |
4 |
OE |
$1.57 |
$20,556 |
D/D |
13,052 |
95,115 |
|
- |
|
| Ray Debanjan |
Chief Financial Officer |
• – – |
2018-08-01 |
4 |
AS |
$26.05 |
$78,150 |
D/D |
(3,000) |
5,928 |
|
- |
|
| Ray Debanjan |
Chief Financial Officer |
• – – |
2018-08-01 |
4 |
OE |
$1.26 |
$3,835 |
D/D |
3,000 |
8,928 |
|
- |
|
286 Records found
|
|
Page 4 of 12 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
